Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00100750 · ClinicalTrials.gov registry record · Phase 1
Tipifarnib and Gemcitabine Hydrochloride in Treating Women With Metastatic Breast Cancer
A Phase 1 study of Stage IV Breast Cancer and Recurrent Breast Carcinoma, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
- 1
- Study location
NCT00100750: Completed Phase 1 study of Stage IV Breast Cancer and Recurrent Breast Carcinoma, sponsored by National Cancer Institute (NCI).
NCT00100750 is a Phase 1 study of Stage IV Breast Cancer and Recurrent Breast Carcinoma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 31 participants, below the 66-participant average among 30 other Stage IV Breast Cancer trials with a reported enrollment target (53% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00100750, a Phase 1 study of Stage IV Breast Cancer and Recurrent Breast Carcinoma, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I/II trial is studying the side effects and best dose of tipifarnib when given together with gemcitabine hydrochloride and to see how well they work in treating women with breast cancer that has spread to other parts of the body. Tipifarnib is a drug that binds to specific proteins on the tumor cells and then kills these cells. Gemcitabine hydrochloride is a chemotherapy drug that may kill tumor cells by preventing cells from dividing. Giving tipifarnib together with gemcitabine hydrochloride may kill more tumor cells.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Tipifarnib
- DRUG Gemcitabine Hydrochloride
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2005-09 |
| Est. Completion | 2010-01 |
| Phase | Phase 1 |
What the finished NCT00100750 record still lists
NCT00100750 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 66-participant average among 30 other Stage IV Breast Cancer trials with a reported enrollment target (53% lower).
The record links to 2 conditions, with Stage IV Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT00100750 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT00100750 about?
NCT00100750 is a clinical study titled "Tipifarnib and Gemcitabine Hydrochloride in Treating Women With Metastatic Breast Cancer". This phase I/II trial is studying the side effects and best dose of tipifarnib when given together with gemcitabine hydrochloride and to see how well they work in treating women with breast cancer that has spread to other parts of the body. Tipifarnib is a drug that binds to specific proteins on the...
What is the current status of trial NCT00100750?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2005-09. Estimated completion is 2010-01.
What conditions does trial NCT00100750 study?
This clinical trial studies the following conditions: Stage IV Breast Cancer, Recurrent Breast Carcinoma.
What interventions are being tested in trial NCT00100750?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Tipifarnib (DRUG), Gemcitabine Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00100750?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00100750 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IV Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00100750's enrollment target sits among peer trials
31 13th of 30 higher than 16 of 30 other Stage IV Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stage IV Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer
RECRUITING · Phase 1
-
BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Decitabine in Treating Patients With Advanced Solid Tumors
COMPLETED · Phase 1
-
4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer
COMPLETED · Phase 1
-
Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia